NCT02257619View on ClinicalTrials.gov

Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

April 30, 2016

Conditions
NSCLC (Non-small Cell Lung Carcinoma)
Interventions
DRUG

Itacitinib

Itacitinib tablets administered orally at 400 mg QD for Part 1 of the study.

DRUG

docetaxel

Administered as an intravenous infusion in the clinic at 75 mg/m\^2 Q3W for Part 1 of the study.

Trial Locations (16)

Unknown

Hot Springs

Los Angeles

Washington D.C.

Orlando

Detroit

Pascagoula

Kansas City

Omaha

Lebanon

Goldsboro

Cleveland

Gettysburg

Hershey

Pawtucket

Spartanburg

Round Rock

Sponsors

Lead Sponsor

Incyte Corporation
All Listed Sponsors
lead

Incyte Corporation

INDUSTRY

NCT02257619 - Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter